Alto Neuroscience News

Alto Neuroscience to Present at the Jefferies Global Healthcare Conference

Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO) today announced that Company management will participate in the Jefferies Global Healthcare Conference, taking place June 5-6, 2024, in New York. Amit Etkin, M.D., Ph.D.,

BusinesswireMay 29 08:05 ET

Express News | Alto Neuroscience Names Michael Hanley As COO

BenzingaMay 21 08:07 ET

Express News | Alto Neuroscience Appoints Michael Hanley as Chief Operating Officer

ReutersMay 21 08:05 ET

Buy Rating for Alto Neuroscience: Promising Trials in MDD and Advances in CIAS Treatment

TipRanksMay 16 04:17 ET

TD Cowen Remains a Buy on Alto Neuroscience, Inc. (ANRO)

TipRanksMay 15 12:16 ET

Alto Neuroscience | 10-Q: Quarterly report

SEC announcementMay 14 16:38 ET · Announcements

Express News | Alto Neuroscience Inc: Qtrly Shr Loss $0.76

ReutersMay 14 16:28 ET

Express News | Alto Neuroscience Q1 2024 GAAP EPS $(0.76) Misses $(0.47) Estimate

BenzingaMay 14 16:22 ET

Alto Neuroscience 1Q Loss/Shr 76c >ANRO

Alto Neuroscience 1Q Loss/Shr 76c >ANRO

Dow JonesMay 14 16:11 ET

Express News | Alto Neuroscience Inc: Patient Enrollment on Track Across Phase 2B Mdd Studies for Alto-100 and Alto-300

ReutersMay 14 16:03 ET

Express News | Alto Neuroscience Inc: Strong Cash Position of Approximately $206 Mln Expected to Support Planned Operations Into 2027

ReutersMay 14 16:03 ET

Express News | Alto Neuroscience Reports First Quarter 2024 Financial Results and Recent Business Highlights

ReutersMay 14 16:03 ET

Alto Neuroscience Announces Data Presentations Highlighting Late-Stage Clinical Pipeline and Robust Platform at Upcoming Scientific Conferences

– Breadth of Alto's pipeline and Precision Psychiatry Platform will be highlighted across twelve posters and presentations at the Society of Biological Psychiatry and American Society of Clinical

BusinesswireMay 9 08:05 ET

Treatment Patch For Schizophrenia: Newly Listed Alto Neuroscience Is Uniquely Positioned In Neuropsychiatry Landscape

Recently listed Alto Neuroscience Inc (NYSE:ANRO) released results from its healthy volunteer Phase 1 study of ALTO-101, a novel PDE4 inhibitor in development for cognitive impairment associated with

BenzingaApr 23 14:55 ET

Alto Neuroscience Schizophrenia Treatment Shows Good Phase 1 Results

Seeking AlphaApr 23 13:21 ET

Express News | Alto Neuroscience Announces Positive Phase 1 Results For ALTO-101, A Novel PDE4 Inhibitor In Development For Schizophrenia

Moomoo 24/7Apr 23 08:09 ET

Express News | Alto Neuroscience Inc - Novel Transdermal Formulation Delivered Significantly Greater Drug Exposure, Fewer Adverse Events Typically Associated With Pde4 Inhibitors

Moomoo 24/7Apr 23 08:06 ET

Express News | Alto Neuroscience Inc - Proof-of-Concept Study in Cognitive Impairment Associated With Schizophrenia (Cias) to Be Initiated in First Half of 2024

Moomoo 24/7Apr 23 08:06 ET

Express News | Alto Neuroscience Inc - Alto-101 Demonstrated a Favorable Pharmacokinetic and Tolerability Profile

Moomoo 24/7Apr 23 08:05 ET

Express News | Alto Neuroscience Announces Positive Phase 1 Results for Alto-101, a Novel Pde4 Inhibitor in Development for Schizophrenia

Moomoo 24/7Apr 23 08:05 ET